Diagnosis and treatment of testicular mixed germ cell tumor: a report of 11 cases
10.3969/j.issn.1009-8291.2023.08.007
- VernacularTitle:睾丸混合性生殖细胞肿瘤11例诊治报告
- Author:
Zujuan SHAN
1
;
Jinrui WANG
1
;
Yanhong YU
1
Author Information
1. Department of Urology, The First People’s Hospital of Yunnan Province Affiliated to Kunming University of Science and Technology, Kunming 650100, China
- Publication Type:Journal Article
- Keywords:
testicular cancer;
retroperitoneal lymph node dissection;
radical orchiectomy;
chemotherapy
- From:
Journal of Modern Urology
2023;28(8):674-678
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To explore the diagnosis and treatment of mixed germ cell tumor (MGCT). 【Methods】 Clinical data of 11 confirmed MGCT cases treated in our hospital during Mar.2017 and Aug.2022 were retrospectively analyzed. The clinical characteristics, treatment methods and therapeutic effects were analyzed. The relevant literature and guidelines were discussed. 【Results】 MGCT cases accounted for 18.3% (11/60) of testicular cancer(TC) cases and 21.2% (11/52) of germ cell tumor (GCT) cases treated in our department during the same period. All 11 MGCT cases had unilateral lesions, which were on the left side in 7 cases, and on the right side in 4 cases, with a ratio of left to right side of 1.75∶1. The age of onset ranged from 21 to 52 years, average (29.8±8.7) years. All cases received unilateral radical orchiectomy(RO), 7 received retroperitoneal lymph node dissection(RPLND) (1 robotic RPLND), 6 received postoperative chemotherapy, and 1 received postoperative radiotherapy. During the follow-up of 2 to 66 [average (31.9±20.9)months] , no recurrence or metastasis were observed. 【Conclusion】 MGCT is a relatively rare malignant tumor in clinical practice, with worse prognosis than seminoma germ cell tumor (SGCT). Standardized diagnosis and treatment based on the special characteristics of each pathological type can improve the survival.
